204.76

5.87% 11.36

After Hours: 204.56 -0.20 -0.10%

Astrazeneca Plc (AZN)

Overview News Price History Option Chain Why AZN Down? Discussions Forecast Stock Split Dividend History

Astrazeneca Plc stock is traded at $204.76, with a volume of 3.46M. It is up +5.87% in the last 24 hours and up +116.33% over the past month. A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales.

Previous Close:

$193.40

Open:

$200.08

24h Volume:

3.46M

Relative Volume:

0.56

Market Cap:

$317.44B

Revenue:

$58.07B

Net Income/Loss:

$9.40B

P/E Ratio:

67.99

EPS:

3.0115

Net Cash Flow:

$9.87B

1W Performance:

+9.23%

1M Performance:

+116.33%

6M Performance:

+176.44%

1Y Performance:

+181.53%

1-Day Range:

$199.19

$204.92

1-Week Range:

$186.58

$204.92

52-Week Range:

$61.24

$204.92

Astrazeneca Plc Stock (AZN) Company Profile

Name

Astrazeneca Plc

Sector

Healthcare (1108)

Industry

Drug Manufacturers - General (20)

Phone

Address

Employee

94,300

Twitter

@AstraZeneca

Next Earnings Date

2026-02-10

Latest SEC Filings

AZN's Discussions on Twitter

Compare AZN vs LLY, JNJ, ABBV, NVS

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
AZN Astrazeneca Plc	204.76	299.82B	58.07B	9.40B	9.87B	3.0115
LLY Lilly Eli Co	1,015.21	917.39B	65.18B	20.64B	6.44B	22.96
JNJ Johnson Johnson	240.86	574.26B	94.19B	26.80B	20.46B	11.05
ABBV Abbvie Inc	220.89	393.14B	61.16B	4.20B	19.68B	2.3671
NVS Novartis Ag Adr	160.06	301.87B	54.72B	14.02B	15.32B	7.1855

Astrazeneca Plc Stock (AZN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-27-26	Initiated	Citigroup	Buy
Oct-27-25	Resumed	Jefferies	Buy
Oct-16-25	Downgrade	Deutsche Bank	Hold → Sell
Apr-15-25	Initiated	Exane BNP Paribas	Outperform
Feb-13-25	Upgrade	UBS	Neutral → Buy
Feb-12-25	Initiated	Morgan Stanley	Overweight
Nov-20-24	Upgrade	UBS	Sell → Neutral
Nov-06-24	Upgrade	Deutsche Bank	Sell → Hold
Sep-13-24	Downgrade	Deutsche Bank	Hold → Sell
May-30-24	Initiated	Goldman	Buy
Apr-16-24	Upgrade	Deutsche Bank	Sell → Hold
Feb-08-24	Downgrade	Deutsche Bank	Hold → Sell
Jan-23-24	Initiated	Morgan Stanley	Overweight
Jan-16-24	Resumed	UBS	Sell
Jan-03-24	Downgrade	Jefferies	Buy → Hold
Dec-18-23	Initiated	HSBC Securities	Buy
Sep-25-23	Upgrade	Jefferies	Hold → Buy
Jul-14-23	Initiated	HSBC Securities	Buy
Jul-12-23	Upgrade	UBS	Neutral → Buy
Jul-05-23	Downgrade	Deutsche Bank	Buy → Hold
Apr-11-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Jan-05-23	Initiated	BMO Capital Markets	Outperform
Sep-15-22	Downgrade	Credit Suisse	Outperform → Neutral
Sep-07-22	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Aug-29-22	Upgrade	Argus	Hold → Buy
Jun-14-22	Downgrade	UBS	Buy → Neutral
Feb-11-22	Upgrade	DZ Bank	Sell → Hold
Dec-07-21	Downgrade	Jefferies	Buy → Hold
Aug-12-21	Resumed	JP Morgan	Overweight
Apr-12-21	Downgrade	Argus	Buy → Hold
Mar-16-21	Upgrade	Jefferies	Hold → Buy
Feb-25-21	Upgrade	UBS	Neutral → Buy
Jan-15-21	Initiated	Deutsche Bank	Buy
Dec-07-20	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Nov-30-20	Upgrade	UBS	Sell → Neutral
Nov-11-20	Upgrade	HSBC Securities	Reduce → Hold
Sep-29-20	Initiated	Berenberg	Buy
Nov-22-19	Initiated	SVB Leerink	Outperform
Oct-25-19	Upgrade	Liberum	Hold → Buy
Apr-02-19	Downgrade	UBS	Neutral → Sell
Feb-05-19	Initiated	Exane BNP Paribas	Outperform
Jan-25-19	Upgrade	Shore Capital	Hold → Buy
Dec-11-18	Resumed	Jefferies	Hold
Oct-09-18	Initiated	Guggenheim	Buy
Aug-16-18	Downgrade	Jefferies	Buy → Hold
Mar-19-18	Upgrade	Jefferies	Hold → Buy
Feb-06-18	Reiterated	Leerink Partners	Mkt Perform
Feb-05-18	Reiterated	Bernstein	Outperform
Jan-18-18	Reiterated	Leerink Partners	Mkt Perform
Dec-29-17	Upgrade	JP Morgan	Neutral → Overweight
Oct-16-17	Upgrade	Credit Suisse	Neutral → Outperform
Sep-25-17	Upgrade	Exane BNP Paribas	Neutral → Outperform
Sep-22-17	Upgrade	Bernstein	Mkt Perform → Outperform

View All

Astrazeneca Plc Stock (AZN) Latest News

04:50 AM

NIH Stops Johnson & Johnson's Blood Thinner Drug Arm In Stroke Trial After Safety Review - Benzinga

02:23 AM

01:23 AM

Former AstraZeneca regional head charged in China (AZN:NYSE) - Seeking Alpha

01:23 AM

01:08 AM

AstraZeneca And Daiichi-Sankyo Stack The Odds For Datroway’s Lung Cancer Bets - Citeline News & Insights

01:08 AM

12:41 PM

How AstraZeneca shot for the moon — and hit - Financial Times

12:41 PM

11:32 AM

China charges former AstraZeneca executive Leon Wang - marketscreener.com

11:32 AM

11:16 AM

AstraZeneca's ex-chief in China formally charged with insurance fraud - The Edge Malaysia

11:16 AM

11:07 AM

Evommune rockets on eczema data; AstraZeneca advances GLP-1 pill - BioPharma Dive

11:07 AM

10:46 AM

Chinese Authorities Charge AstraZeneca's Ex-China Business Head - marketscreener.com

10:46 AM

10:45 AM

Citi maintains 'buy' on AstraZeneca with £170 target, cites sector-best pipeline - Yahoo Finance UK

10:45 AM

09:04 AM

AstraZeneca PLC (NYSE:AZN) Q4 2025 Earnings Call Transcript - Insider Monkey

09:04 AM

09:00 AM

$3.4M for 47 local groups tackling care gaps, nutrition and lung disease - Stock Titan

09:00 AM

08:25 AM

China charges former AstraZeneca executive - Financial Times

08:25 AM

08:16 AM

AstraZeneca PLC (NYSE:AZN) Q4 2025 earnings call transcript - MSN

08:16 AM

08:00 AM

What's Driving the Market Sentiment Around AstraZeneca PLC? - Benzinga

08:00 AM

07:28 AM

AstraZeneca PLC (NASDAQ:AZN) Sees Significant Drop in Short Interest - MarketBeat

07:28 AM

03:40 AM